Tag
In a propensity‑matched Ontario cohort of women with chronic severe coronary artery disease, CABG was associated with lower long‑term MACCE and all‑cause mortality than PCI over a median 5.1 years.
The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.
In high bleeding risk patients undergoing PCI, aspirin-free prasugrel monotherapy fails to reduce major bleeding and shows increased myocardial infarction risk in ACS but not non-ACS patients, suggesting selective use post-PCI.
Recent study shows intravascular imaging-guided PCI may offer comparable 3-year outcomes to CABG in patients with left main or 3-vessel coronary disease, challenging prior assumptions favoring surgery.
The OPTION-STEMI trial evaluated the safety and efficacy of immediate versus staged complete revascularisation during index admission in STEMI patients with multivessel disease, finding no non-inferiority of immediate approach at 1 year.
The ISCHEMIA trial reveals that both PCI and CABG improve health status over conservative management in chronic coronary disease, with CABG offering superior angina relief at 1 year but similar benefits to PCI by 3 years.
Post-PCI myocardial injury defined by elevated CKMB is common and linked to increased long-term mortality, with more complex coronary anatomy predicting the injury occurrence.
Posthoc analysis of TWILIGHT shows that ischemic risk rises with the number of high‑risk features, bleeding does not, and ticagrelor monotherapy after 3 months reduces bleeding versus ticagrelor plus aspirin without increasing ischemic even
The TCW trial demonstrates that FFR-guided PCI plus TAVI is non-inferior and even superior to SAVR plus CABG in elderly patients with severe aortic stenosis and complex coronary artery disease.
